MetLife Investment Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.9M | Sell |
284,053
-21,053
| -7% | -$2.77M | 0.16% | 84 |
|
|
2026
Q1 | $42.5M | Sell |
305,106
-8,557
| -3% | -$1.2M | 0.22% | 63 |
|
|
2025
Q4 | $38.5M | Sell |
313,663
-10,154
| -3% | -$1.23M | 0.19% | 80 |
|
|
2025
Q3 | $35.9M | Sell |
323,817
-8,427
| -3% | -$958K | 0.17% | 86 |
|
|
2025
Q2 | $36.8M | Buy |
332,244
+8,513
| +3% | +$906K | 0.22% | 68 |
|
|
2025
Q1 | $36.3M | Sell |
323,731
-6,167
| -2% | -$636K | 0.2% | 74 |
|
|
2024
Q4 | $30.5M | Buy |
329,898
+6,109
| +2% | +$550K | 0.17% | 89 |
|
|
2024
Q3 | $27.1M | Sell |
323,789
-8,561
| -3% | -$653K | 0.16% | 102 |
|
|
2024
Q2 | $22.8M | Buy |
332,350
+40,522
| +14% | +$2.7M | 0.14% | 118 |
|
|
2024
Q1 | $21.4M | Sell |
291,828
-10,737
| -4% | -$826K | 0.14% | 117 |
|
|
2023
Q4 | $24.5M | Sell |
302,565
-5,714
| -2% | -$445K | 0.18% | 98 |
|
|
2023
Q3 | $23.1M | Sell |
308,279
-8,376
| -3% | -$644K | 0.18% | 92 |
|
|
2023
Q2 | $24.4M | Sell |
316,655
-5,343
| -2% | -$426K | 0.18% | 97 |
|
|
2023
Q1 | $26.7M | Sell |
321,998
-5,597
| -2% | -$464K | 0.19% | 89 |
|
|
2022
Q4 | $28.1M | Sell |
327,595
-5,146
| -2% | -$408K | 0.21% | 82 |
|
|
2022
Q3 | $20.5M | Sell |
332,741
-5,198
| -2% | -$328K | 0.17% | 94 |
|
|
2022
Q2 | $20.9M | Sell |
337,939
-3,402
| -1% | -$211K | 0.16% | 103 |
|
|
2022
Q1 | $20.3M | Buy |
341,341
+64,195
| +23% | +$4.1M | 0.13% | 122 |
|
|
2021
Q4 | $20.1M | Sell |
277,146
-6,040
| -2% | -$416K | 0.17% | 100 |
|
|
2021
Q3 | $19.8M | Sell |
283,186
-7,589
| -3% | -$533K | 0.18% | 100 |
|
|
2021
Q2 | $20M | Sell |
290,775
-8,670
| -3% | -$579K | 0.18% | 101 |
|
|
2021
Q1 | $19.4M | Sell |
299,445
-4,981
| -2% | -$321K | 0.18% | 100 |
|
|
2020
Q4 | $17.7M | Sell |
304,426
-13,447
| -4% | -$811K | 0.17% | 106 |
|
|
2020
Q3 | $20.1M | Sell |
317,873
-10,094
| -3% | -$700K | 0.22% | 80 |
|
|
2020
Q2 | $25.2M | Buy |
327,967
+1,860
| +0.6% | +$143K | 0.29% | 64 |
|
|
2020
Q1 | $24.4M | Sell |
326,107
-9,978
| -3% | -$689K | 0.33% | 58 |
|
|
2019
Q4 | $21.8M | Sell |
336,085
-8,563
| -2% | -$558K | 0.23% | 80 |
|
|
2019
Q3 | $21.8M | Sell |
344,648
-5,842
| -2% | -$382K | 0.24% | 77 |
|
|
2019
Q2 | $23.7M | Sell |
350,490
-12,090
| -3% | -$795K | 0.25% | 72 |
|
|
2019
Q1 | $23.6M | Sell |
362,580
-7,373
| -2% | -$490K | 0.26% | 73 |
|
|
2018
Q4 | $23.1M | Sell |
369,953
-7,157
| -2% | -$500K | 0.28% | 68 |
|
|
2018
Q3 | $29.1M | Sell |
377,110
-5,657
| -1% | -$427K | 0.3% | 63 |
|
|
2018
Q2 | $27.1M | Sell |
382,767
-11,453
| -3% | -$809K | 0.32% | 54 |
|
|
2018
Q1 | $29.7M | Sell |
394,220
-9,950
| -2% | -$791K | 0.35% | 51 |
|
|
2017
Q4 | $29M | Buy |
+404,170
| New | +$30.7M | 0.33% | 51 |
|
Other funds holding GILD
MetLife Investment Management's GILD Position: Q2 2026 in Review
MetLife Investment Management reduced its Gilead Sciences (GILD) stake by 6.9% in Q2 2026, selling an estimated $2.77M and leaving 284,053 shares worth $35.9M. The position accounts for 0.16% of the portfolio, ranked #84.
MetLife Investment Management first reported a position in GILD in Q4 2017 and has held it in 35 quarters since. The position peaked at $42.5M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- MetLife Investment Management held 284,053 shares of Gilead Sciences worth $35.9M as of Q2 2026.
- MetLife Investment Management sold 21,053 Gilead Sciences shares in Q2 2026, an estimated $2.77M.
- Gilead Sciences made up 0.16% of MetLife Investment Management's portfolio in Q2 2026, its #84 holding.
- MetLife Investment Management first reported a position in Gilead Sciences in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Gilead Sciences position peaked at $42.5M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.